Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

PET molecular imaging of phosphodiesterase 10A: An early biomarker of Huntington's disease progression.

Fazio P, Fitzer-Attas CJ, Mrzljak L, Bronzova J, Nag S, Warner JH, Landwehrmeyer B, Al-Tawil N, Halldin C, Forsberg A, Ware J, Dilda V, Wood A, Sampaio C, Varrone A; PEARL-HD and LONGPDE10 study collaborators.

Mov Disord. 2020 Jan 22. doi: 10.1002/mds.27963. [Epub ahead of print]

PMID:
31967355
2.

New approach in radiometabolite analysis of positron emission tomography (PET) radioligands; lead-shielded microextraction by packed sorbent as a tool for in vivo radiometabolite analysis of [11C]SMW139 in rat plasma.

Moein MM, Tóth M, Tari L, Varrone A, Abdel-Rehim M, Halldin C.

Talanta. 2020 Feb 1;208:120449. doi: 10.1016/j.talanta.2019.120449. Epub 2019 Oct 5.

PMID:
31816716
3.

Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study.

Tuisku J, Plavén-Sigray P, Gaiser EC, Airas L, Al-Abdulrasul H, Brück A, Carson RE, Chen MK, Cosgrove KP, Ekblad L, Esterlis I, Farde L, Forsberg A, Halldin C, Helin S, Kosek E, Lekander M, Lindgren N, Marjamäki P, Rissanen E, Sucksdorff M, Varrone A; HRRT [11C ]PBR28 study group, Collste K, Gallezot JD, Hillmer A, Huang Y, Höglund CO, Johansson J, Jucaite A, Lampa J, Nabulsi N, Pittman B, Sandiego CM, Stenkrona P, Rinne J, Matuskey D, Cervenka S.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2329-2338. doi: 10.1007/s00259-019-04403-7. Epub 2019 Jul 30.

4.

Performance Evaluation of a High-Resolution Nonhuman Primate PET/CT System.

Sarnyai Z, Nagy K, Patay G, Molnár M, Rosenqvist G, Tóth M, Takano A, Gulyás B, Major P, Halldin C, Varrone A.

J Nucl Med. 2019 Dec;60(12):1818-1824. doi: 10.2967/jnumed.117.206243. Epub 2019 Jul 13.

PMID:
31302634
5.

Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease.

Zeitler B, Froelich S, Marlen K, Shivak DA, Yu Q, Li D, Pearl JR, Miller JC, Zhang L, Paschon DE, Hinkley SJ, Ankoudinova I, Lam S, Guschin D, Kopan L, Cherone JM, Nguyen HB, Qiao G, Ataei Y, Mendel MC, Amora R, Surosky R, Laganiere J, Vu BJ, Narayanan A, Sedaghat Y, Tillack K, Thiede C, Gärtner A, Kwak S, Bard J, Mrzljak L, Park L, Heikkinen T, Lehtimäki KK, Svedberg MM, Häggkvist J, Tari L, Tóth M, Varrone A, Halldin C, Kudwa AE, Ramboz S, Day M, Kondapalli J, Surmeier DJ, Urnov FD, Gregory PD, Rebar EJ, Muñoz-Sanjuán I, Zhang HS.

Nat Med. 2019 Jul;25(7):1131-1142. doi: 10.1038/s41591-019-0478-3. Epub 2019 Jul 1.

PMID:
31263285
6.

A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer.

Varrone A, Varnäs K, Jucaite A, Cselényi Z, Johnström P, Schou M, Vazquez-Romero A, Moein MM, Halldin C, Brown AP, Vishwanathan K, Farde L.

J Cereb Blood Flow Metab. 2019 Apr 20:271678X19843776. doi: 10.1177/0271678X19843776. [Epub ahead of print]

PMID:
31006308
7.

Synthesis, 3 H-labelling and in vitro evaluation of a substituted dipiperidine alcohol as a potential ligand for chemokine receptor 2.

Artelsmair M, Miranda-Azpiazu P, Kingston L, Bergare J, Schou M, Varrone A, Elmore CS.

J Labelled Comp Radiopharm. 2019 May 30;62(6):265-279. doi: 10.1002/jlcr.3731.

8.

In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [18F]MNI-659.

Svedberg MM, Varnäs K, Varrone A, Mitsios N, Mulder J, Gulyás B, Beaumont V, Munoz-Sanjuan I, Zaleska MM, Schmidt CJ, Halldin C, Mrzljak L.

Brain Res. 2019 May 15;1711:140-145. doi: 10.1016/j.brainres.2019.01.021. Epub 2019 Jan 18.

PMID:
30664847
9.

Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT-a clinical comparison.

Jakobson Mo S, Axelsson J, Jonasson L, Larsson A, Ögren MJ, Ögren M, Varrone A, Eriksson L, Bäckström D, Af Bjerkén S, Linder J, Riklund K.

EJNMMI Res. 2018 Nov 15;8(1):100. doi: 10.1186/s13550-018-0450-0.

10.

SPECT Molecular Imaging in Familial Parkinson's Disease.

Varrone A, Pellecchia MT.

Int Rev Neurobiol. 2018;142:225-260. doi: 10.1016/bs.irn.2018.09.004. Epub 2018 Oct 30. Review.

PMID:
30409254
11.

Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.

Fazio P, Paucar M, Svenningsson P, Varrone A.

Curr Neurol Neurosci Rep. 2018 Oct 5;18(12):85. doi: 10.1007/s11910-018-0890-y. Review.

12.

PET imaging of [11C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding.

Varnäs K, Cselényi Z, Jucaite A, Halldin C, Svenningsson P, Farde L, Varrone A.

Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):367-375. doi: 10.1007/s00259-018-4161-6. Epub 2018 Oct 1.

13.

Increased Brain Exposure of an Alpha-Synuclein Fibrillization Modulator by Utilization of an Activated Ester Prodrug Strategy.

Cairns AG, Vazquez-Romero A, Mahdi Moein M, Ådén J, Elmore CS, Takano A, Arakawa R, Varrone A, Almqvist F, Schou M.

ACS Chem Neurosci. 2018 Nov 21;9(11):2542-2547. doi: 10.1021/acschemneuro.8b00236. Epub 2018 Jun 19.

PMID:
29901990
14.

Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain.

Chiotis K, Stenkrona P, Almkvist O, Stepanov V, Ferreira D, Arakawa R, Takano A, Westman E, Varrone A, Okamura N, Shimada H, Higuchi M, Halldin C, Nordberg A.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1605-1617. doi: 10.1007/s00259-018-4012-5. Epub 2018 May 12.

15.

Nigrostriatal dopamine transporter availability in early Parkinson's disease.

Fazio P, Svenningsson P, Cselényi Z, Halldin C, Farde L, Varrone A.

Mov Disord. 2018 Apr;33(4):592-599. doi: 10.1002/mds.27316. Epub 2018 Feb 13.

PMID:
29436751
16.

Simplified estimation of binding parameters based on image-derived reference tissue models for dopamine transporter bindings in non-human primates using [18F]FE-PE2I and PET.

Odano I, Varrone A, Hosoya T, Sakaguchi K, Gulyás B, Padmanabhan P, Ghosh KK, Yang CT, Guenther I, Wang Z, Serrano R, Chimon NG, Halldin C.

Am J Nucl Med Mol Imaging. 2017 Dec 20;7(6):246-254. eCollection 2017.

17.

Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects.

Lizana H, Johansson L, Axelsson J, Larsson A, Ögren M, Linder J, Halldin C, Varrone A, Mo SJ.

J Nucl Med. 2018 Aug;59(8):1275-1280. doi: 10.2967/jnumed.117.197186. Epub 2018 Jan 18.

18.

Revisiting the Logan plot to account for non-negligible blood volume in brain tissue.

Schain M, Fazio P, Mrzljak L, Amini N, Al-Tawil N, Fitzer-Attas C, Bronzova J, Landwehrmeyer B, Sampaio C, Halldin C, Varrone A.

EJNMMI Res. 2017 Aug 18;7(1):66. doi: 10.1186/s13550-017-0314-z.

19.

Assessment of simplified ratio-based approaches for quantification of PET [11C]PBR28 data.

Matheson GJ, Plavén-Sigray P, Forsberg A, Varrone A, Farde L, Cervenka S.

EJNMMI Res. 2017 Dec;7(1):58. doi: 10.1186/s13550-017-0304-1. Epub 2017 Jul 21.

20.

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.

Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B.

Lancet Neurol. 2017 Aug;16(8):661-676. doi: 10.1016/S1474-4422(17)30159-X. Epub 2017 Jul 11. Review.

PMID:
28721928
21.

Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework.

Sonni I, Ratib O, Boccardi M, Picco A, Herholz K, Nobili F, Varrone A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:228-242. doi: 10.1016/j.neurobiolaging.2016.04.026. Review.

PMID:
28317651
22.

Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.

Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, Garibotto V, Herholz K, Nobili F, Nordberg A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:214-227. doi: 10.1016/j.neurobiolaging.2016.07.012. Review.

PMID:
28317650
23.

Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.

Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, Nobili F, Ratib O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:183-195. doi: 10.1016/j.neurobiolaging.2016.03.033. Review.

PMID:
28317648
24.

Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18F-MNI-659 and 11C-raclopride with correction for partial volume effect.

Fazio P, Schain M, Mrzljak L, Amini N, Nag S, Al-Tawil N, Fitzer-Attas CJ, Bronzova J, Landwehrmeyer B, Sampaio C, Halldin C, Varrone A.

Neuroimage. 2017 May 15;152:330-339. doi: 10.1016/j.neuroimage.2017.02.047. Epub 2017 Feb 28.

PMID:
28254508
25.

The immune response of the human brain to abdominal surgery.

Forsberg A, Cervenka S, Jonsson Fagerlund M, Rasmussen LS, Zetterberg H, Erlandsson Harris H, Stridh P, Christensson E, Granström A, Schening A, Dymmel K, Knave N, Terrando N, Maze M, Borg J, Varrone A, Halldin C, Blennow K, Farde L, Eriksson LI.

Ann Neurol. 2017 Apr;81(4):572-582. doi: 10.1002/ana.24909. Epub 2017 Apr 11.

26.

[123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods.

Tossici-Bolt L, Dickson JC, Sera T, Booij J, Asenbaun-Nan S, Bagnara MC, Borght TV, Jonsson C, de Nijs R, Hesse S, Koulibaly PM, Akdemir UO, Koole M, Tatsch K, Varrone A.

EJNMMI Phys. 2017 Dec;4(1):8. doi: 10.1186/s40658-017-0175-6. Epub 2017 Jan 28.

27.

In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects.

Delnomdedieu M, Forsberg A, Ogden A, Fazio P, Yu CR, Stenkrona P, Duvvuri S, David W, Al-Tawil N, Vitolo OV, Amini N, Nag S, Halldin C, Varrone A.

Neuropharmacology. 2017 May 1;117:171-181. doi: 10.1016/j.neuropharm.2017.01.016. Epub 2017 Jan 22.

PMID:
28122201
28.

The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging.

Dickson JC, Tossici-Bolt L, Sera T, Booij J, Ziebell M, Morbelli S, Assenbaum-Nan S, Borght TV, Pagani M, Kapucu OL, Hesse S, Van Laere K, Darcourt J, Varrone A, Tatsch K.

EJNMMI Res. 2017 Dec;7(1):10. doi: 10.1186/s13550-016-0253-0. Epub 2017 Jan 24.

29.

Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.

Beaumont V, Zhong S, Lin H, Xu W, Bradaia A, Steidl E, Gleyzes M, Wadel K, Buisson B, Padovan-Neto FE, Chakroborty S, Ward KM, Harms JF, Beltran J, Kwan M, Ghavami A, Häggkvist J, Tóth M, Halldin C, Varrone A, Schaab C, Dybowski JN, Elschenbroich S, Lehtimäki K, Heikkinen T, Park L, Rosinski J, Mrzljak L, Lavery D, West AR, Schmidt CJ, Zaleska MM, Munoz-Sanjuan I.

Neuron. 2016 Dec 21;92(6):1220-1237. doi: 10.1016/j.neuron.2016.10.064. Epub 2016 Dec 1.

30.

Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex.

Häggkvist J, Tóth M, Tari L, Varnäs K, Svedberg M, Forsberg A, Nag S, Dominguez C, Munoz-Sanjuan I, Bard J, Wityak J, Varrone A, Halldin C, Mrzljak L.

J Nucl Med. 2017 Apr;58(4):617-622. doi: 10.2967/jnumed.116.180497. Epub 2016 Nov 10.

31.

Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.

Sturm S, Forsberg A, Nave S, Stenkrona P, Seneca N, Varrone A, Comley RA, Fazio P, Jamois C, Nakao R, Ejduk Z, Al-Tawil N, Akenine U, Halldin C, Andreasen N, Ricci B.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):382-391. doi: 10.1007/s00259-016-3510-6. Epub 2016 Sep 16.

32.

Guidelines to PET measurements of the target occupancy in the brain for drug development.

Takano A, Varrone A, Gulyás B, Salvadori P, Gee A, Windhorst A, Vercouillie J, Bormans G, Lammertsma AA, Halldin C.

Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2255-2262. Epub 2016 Aug 11.

33.

Low serotonin1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder.

Tiger M, Farde L, Rück C, Varrone A, Forsberg A, Lindefors N, Halldin C, Lundberg J.

Psychiatry Res Neuroimaging. 2016 Jul 30;253:36-42. doi: 10.1016/j.pscychresns.2016.04.016. Epub 2016 Apr 27.

34.

Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.

Sonni I, Fazio P, Schain M, Halldin C, Svenningsson P, Farde L, Varrone A.

J Nucl Med. 2016 Oct;57(10):1529-1534. Epub 2016 May 26.

35.

Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: Validation using postmortem autoradiography data.

Fazio P, Schain M, Varnäs K, Halldin C, Farde L, Varrone A.

Neuroimage. 2016 Jun;133:313-320. doi: 10.1016/j.neuroimage.2016.03.019. Epub 2016 Mar 17.

PMID:
26994829
36.

In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects.

Kanegawa N, Collste K, Forsberg A, Schain M, Arakawa R, Jucaite A, Lekander M, Olgart Höglund C, Kosek E, Lampa J, Halldin C, Farde L, Varrone A, Cervenka S.

Brain Behav Immun. 2016 May;54:149-157. doi: 10.1016/j.bbi.2016.01.019. Epub 2016 Jan 25.

PMID:
26820224
37.

Reduction in camera-specific variability in [(123)I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls.

Buchert R, Kluge A, Tossici-Bolt L, Dickson J, Bronzel M, Lange C, Asenbaum S, Booij J, Atay Kapucu LÖ, Svarer C, Koulibaly PM, Nobili F, Pagani M, Sabri O, Sera T, Tatsch K, Vander Borght T, Van Laere K, Varrone A, Iida H.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1323-36. doi: 10.1007/s00259-016-3309-5. Epub 2016 Jan 27.

PMID:
26816194
38.

Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes.

Albert NL, Unterrainer M, Diemling M, Xiong G, Bartenstein P, Koch W, Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, Kapucu LÖ, Kluge A, Ziebell M, Darcourt J, Nobili F, Pagani M, Sabri O, Hesse S, Borght TV, Van Laere K, Tatsch K, la Fougère C.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1315-22. doi: 10.1007/s00259-015-3304-2. Epub 2016 Jan 18.

PMID:
26780619
39.

In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl.

Nag S, Fazio P, Lehmann L, Kettschau G, Heinrich T, Thiele A, Svedberg M, Amini N, Leesch S, Catafau AM, Hannestad J, Varrone A, Halldin C.

J Nucl Med. 2016 Feb;57(2):315-20. doi: 10.2967/jnumed.115.161083. Epub 2015 Nov 19.

40.

Test-retest reproducibility of [(11)C]PBR28 binding to TSPO in healthy control subjects.

Collste K, Forsberg A, Varrone A, Amini N, Aeinehband S, Yakushev I, Halldin C, Farde L, Cervenka S.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):173-183. doi: 10.1007/s00259-015-3149-8. Epub 2015 Aug 22.

PMID:
26293827
41.

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease.

Jucaite A, Svenningsson P, Rinne JO, Cselényi Z, Varnäs K, Johnström P, Amini N, Kirjavainen A, Helin S, Minkwitz M, Kugler AR, Posener JA, Budd S, Halldin C, Varrone A, Farde L.

Brain. 2015 Sep;138(Pt 9):2687-700. doi: 10.1093/brain/awv184. Epub 2015 Jul 1.

PMID:
26137956
42.

ABC transporter-dependent brain uptake of the 5-HT1B receptor radioligand [ (11)C]AZ10419369: a comparative PET study in mouse, rat, and guinea pig.

Tóth M, Häggkvist J, Varrone A, Finnema SJ, Doorduin J, Tokunaga M, Higuchi M, Gulyás B, Halldin C.

EJNMMI Res. 2014 Dec;4(1):64. doi: 10.1186/s13550-014-0064-0. Epub 2014 Nov 30.

43.

Positron Emission Tomography studies with [11C]PBR28 in the Healthy Rodent Brain: Validating SUV as an Outcome Measure of Neuroinflammation.

Tóth M, Doorduin J, Häggkvist J, Varrone A, Amini N, Halldin C, Gulyás B.

PLoS One. 2015 May 21;10(5):e0125917. doi: 10.1371/journal.pone.0125917. eCollection 2015.

44.

5-HT1B receptor imaging and cognition: a positron emission tomography study in control subjects and Parkinson's disease patients.

Varrone A, Svenningsson P, Marklund P, Fatouros-Bergman H, Forsberg A, Halldin C, Nilsson LG, Farde L.

Synapse. 2015 Jul;69(7):365-74. doi: 10.1002/syn.21823. Epub 2015 May 25.

PMID:
25914348
45.

Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.

Fazio P, Svenningsson P, Forsberg A, Jönsson EG, Amini N, Nakao R, Nag S, Halldin C, Farde L, Varrone A.

J Nucl Med. 2015 May;56(5):714-20. doi: 10.2967/jnumed.114.152421. Epub 2015 Mar 19.

46.

Diurnal and seasonal variation of the brain serotonin system in healthy male subjects.

Matheson GJ, Schain M, Almeida R, Lundberg J, Cselényi Z, Borg J, Varrone A, Farde L, Cervenka S.

Neuroimage. 2015 May 15;112:225-231. doi: 10.1016/j.neuroimage.2015.03.007. Epub 2015 Mar 12.

PMID:
25772667
47.

Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients.

Paul G, Zachrisson O, Varrone A, Almqvist P, Jerling M, Lind G, Rehncrona S, Linderoth B, Bjartmarz H, Shafer LL, Coffey R, Svensson M, Mercer KJ, Forsberg A, Halldin C, Svenningsson P, Widner H, Frisén J, Pålhagen S, Haegerstrand A.

J Clin Invest. 2015 Mar 2;125(3):1339-46. doi: 10.1172/JCI79635. Epub 2015 Feb 17.

48.

Amphetamine decreases α2C-adrenoceptor binding of [11C]ORM-13070: a PET study in the primate brain.

Finnema SJ, Hughes ZA, Haaparanta-Solin M, Stepanov V, Nakao R, Varnäs K, Varrone A, Arponen E, Marjamäki P, Pohjanoksa K, Vuorilehto L, Babalola PA, Solin O, Grimwood S, Sallinen J, Farde L, Scheinin M, Halldin C.

Int J Neuropsychopharmacol. 2014 Dec 13;18(3). pii: pyu081. doi: 10.1093/ijnp/pyu081.

49.

Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer's disease patients and control subjects.

Varrone A, Oikonen V, Forsberg A, Joutsa J, Takano A, Solin O, Haaparanta-Solin M, Nag S, Nakao R, Al-Tawil N, Wells LA, Rabiner EA, Valencia R, Schultze-Mosgau M, Thiele A, Vollmer S, Dyrks T, Lehmann L, Heinrich T, Hoffmann A, Nordberg A, Halldin C, Rinne JO.

Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):438-46. doi: 10.1007/s00259-014-2955-8. Epub 2014 Nov 21.

PMID:
25412766
50.

Distinct regional age effects on [11C]AZ10419369 binding to 5-HT1B receptors in the human brain.

Nord M, Cselenyi Z, Forsberg A, Rosenqvist G, Tiger M, Lundberg J, Varrone A, Farde L.

Neuroimage. 2014 Dec;103:303-308. doi: 10.1016/j.neuroimage.2014.09.040. Epub 2014 Sep 23.

PMID:
25255943

Supplemental Content

Loading ...
Support Center